DRKS00009626招募中2 期
A Study of MEK162 in NRAS mutated metastatic melanoma patients with brain metastases - Brain-MEK-Study
niversitätsSpital ZürichDermatologische KlinikSwitzerland0 个研究点目标入组 25 人开始时间: 2015年11月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •1. Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow-up. Procedures conducted as part of the subject’s routine clinical management (e.g., blood count, imaging study) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol.
- •2. Male or female = 18 years of age
- •3. Histologically confirmed metastatic melanoma (Stage IV, AJCC) with documented mutational status (NRAS mutation)
- •4. Presence of brain metastases (pretreated, not pretreated, asymptomatic patients that are not eligible in other clinical trials or symptomatic patients). Pretreated patients should have documented progression of disease after previous treatment to be included in the trial. Symptomatic patients should have a stable or decreasing steroid dose.
- •5. Prior PD-1 antibody blockers and any other prior immunotherapy are allowed
- •6. Stable or decreasing corticosteroids dose within 1 week prior to study entry
- •7. Patients with either measurable or non-measurable disease (RECIST Version 1.1)
- •8. Present lesions must be measurable (either by CT-scan, MRI, or PET/CT)
- •9. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2
- •10. Patients must have recovered from all side-effects of their most recent systemic or local treatment for metastatic melanoma
- •11. Adequate hematologic, renal and liver function as defined by the following laboratory values performed within 7 days prior to initiation of dosing
- •- Absolute neutrophil count (ANC) = 1.5 x 109/L
- •- Platelet count = 100 x 109/L
- •- Hemoglobin = 9 g/dL
- •- Serum creatinine = 1.5 times the upper limit of normal (ULN) or creatinine clearance (CrCl) > 50 mL/h by the Cockroft–Gault formula
- •- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 times ULN (= 5 times ULN if considered due to tumor)
- •- Serum bilirubin = 1.5 times ULN
- •- Alkaline phosphatase = 2.5 times ULN (= 5 times ULN if considered due to tumor)
- •12. Adequate cardiac function:
- •left ventricular ejection fraction (LVEF) = 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram,
- •QTc interval = 480 ms;
- •13. Able to take oral medications;
- •14. Patient is deemed by the Investigator to have the initiative and means to be complaint with the protocol (treatment and follow-up);
- •15. Negative serum pregnancy test within 28 days prior to commencement of dosing in pre menopausal women or if she is of non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had a hysterectomy, a bilateral oophorectomy (ovariectomy), a bilateral tubal ligation, is post-menopausal.
- •16. Fertile men and women must use an effective method of contraception during treatment and for at least 2 months after completion of treatment as directed by their physician.
- •17. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule
排除标准
- •1.Non-cutaneous melanoma;
- •2.Cutaneous melanoma with BRAF V600 mutation or NRAS wildtype/unknown;
- •3.Leptomeningeal disease
- •4.History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes);
- •5.History of retinal degenerative disease;
- •6.History of allogeneic bone marrow transplantation or organ transplantation;
- •7.History of Gilbert’s syndrome;
- •8.Previous or concurrent malignancy with the following exceptions:
- •adequately treated basal cell or squamous cell carcinoma of the skin (adequate wound healing is required prior to study entry),
- •in situ carcinoma of the cervix, treated curatively and without evidence of recurrence for at least 3 years prior to the study,
- •a primary malignancy which has been completely resected and in complete remission for =5 years;
- •9.Prior therapy with a MEK- inhibitor;
- •10.Treatment with any cytotoxic and/or investigational cytotoxic drug or targeted therapy = 2 weeks prior to Day 1 of study
- •11.Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:
- •History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) <6 months prior to screening,
- •Symptomatic chronic heart failure, history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality <6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia;
- •12.Uncontrolled arterial hypertension despite medical treatment;
- •13.Known positive serology for HIV, active hepatitis B, and/or active hepatitis C infection
- •14.Patients who have neuromuscular disorders that are associated with elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy);
- •15.Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment. NB: Muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK162 treatment;
- •16.Impairment of gastrointestinal function or gastrointestinal disease (e.g., uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection);
- •17.Any other condition that would, in the Investigator’s judgment, contraindicate the patient’s participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc.;
- •18.Patients who have who have not recovered from side effects of major surgery procedures;
- •19.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test;
- •20.Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for 8 weeks after study drug discontinuation. Highly effective contraception methods include:
- •Total abstinence including lesbians and nuns of any religious affiliation when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g
研究者
相似试验
进行中（未招募）
不适用
Expanded Access Study of MEK162 in Metastatic or Unresectable NRAS Mutation-positive MelanomaMetastatic or Unresectable NRAS Mutation-positive MelanomaMedDRA version: 16.1Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2014-001558-40-HUzsoki Hospital
进行中（未招募）
1 期
Study comparing the efficacy of MEK162 versus dacarbazine in unresectable or metastatic NRAS mutation-positive melanoma (NEMO)metastatic or unresectable cutaneous melanomaMedDRA version: 20.0Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2012-003593-51-BEArray BioPharma Inc.393
进行中（未招募）
1 期
Study comparing the efficacy of MEK162 versus dacarbazine in unresectable or metastatic NRAS mutation-positive melanoma (NEMO)Metastatic or unresectable cutaneous melanomaMedDRA version: 21.1 Level: LLT Classification code 10053571 Term: Melanoma System Organ Class: 100000004864EUCTR2012-003593-51-SEArray BioPharma Inc.393
进行中（未招募）
1 期
Study comparing the efficacy of MEK162 versus dacarbazine in unresectable or metastatic NRAS mutation-positive melanoma (NEMO)metastatic or unresectable cutaneous melanomaMedDRA version: 20.0Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2012-003593-51-PTArray BioPharma402
进行中（未招募）
不适用
Study comparing the efficacy of MEK162 versus dacarbazine in unresectable or metastatic NRAS mutation-positive melanoma (NEMO)metastatic or unresectable cutaneous melanomaMedDRA version: 18.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2012-003593-51-SKArray BioPharma Inc.393